The Wnt pathway, cell-cycle activation and β-amyloid: Novel therapeutic strategies in Alzheimer's disease?

Trends in Pharmacological Sciences

Volumn 24, Issue 5, 2003, Pages 233-238

  Caricasole, Andrea ^a,b   Copani, Agata ^c   Caruso, Alessandra ^a   Caraci, Filippo ^c   Iacovelli, Luisa ^a,d   Sortino, Maria Angela ^c   Terstappen, Georg C ^b   Nicoletti, Ferdinando ^a,d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Siena Biotech SpA   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d IRCCS NEUROMED   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; 7 HYDROXYSTAUROSPORINE; AMYLOID BETA PROTEIN; CELECOXIB; DNA DIRECTED DNA POLYMERASE BETA INHIBITOR; EGLUMETAD; ESTROGEN; FLAVOPIRIDOL; MEMANTINE; PROTEIN INHIBITOR; PYRROLE DERIVATIVE; ROFECOXIB; UNCLASSIFIED DRUG; WNT PROTEIN;

ALZHEIMER DISEASE; BRAIN DEVELOPMENT; BRAIN NERVE CELL; BRAIN TOXICITY; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECT; MITOSIS; MOLECULAR DYNAMICS; NERVE CELL DIFFERENTIATION; NERVE DEGENERATION; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STEM CELL;

EID: 0037723974     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(03)00100-7     Document Type: Review

References (51)

1. Bierer L.M., et al. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Arch. Neurol. 52:1995;81-88.
2. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 297:2002;353-356.
3. Vincent I., et al. Aberrant expression of mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer's disease brain. J. Neurosci. 17:1997;3588-3598.
4. Nagy Z., et al. The cell division cycle and the pathophysiology of Alzheimer's disease. Neuroscience. 87:1998;731-739.
5. McShea A., et al. Re-entry into the cell cycle: a mechanism for neurodegeneration in Alzheimer disease. Med. Hypotheses. 52:1999;525-527.
6. Raina A.K., et al. Cyclin' toward dementia: cell cycle abnormalities and abortive oncogenesis in Alzheimer's disease. J. Neurosci. Res. 61:2000;128-133.
7. Copani A., et al. Mitotic signaling by beta-amyloid causes neuronal death. FASEB J. 13:1999;2225-2234.
8. Copani A., et al. Erratic expression of DNA polymerases by β-amyloid causes neuronal death. FASEB J. 16:2002;2006-2008.
9. Yang Y., et al. DNA replication precedes neuronal cell death in Alzheimer's disease. J. Neurosci. 21:2001;2661-2668.
10. Zheng W.H., et al. Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. Neuroscience. 115:2002;201-211.
11. Otth C., et al. AbetaPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576. J. Alzheimers Dis. 4:2002;417-430.
12. Takashima A., et al. Activation of tau protein kinase I/glycogen synthase kinase-3β by βamyloid peptide (25-35) enhances phosphorylation of tau in hippocampal neurons. Neurosci. Res. 31:1998;317-323.
13. Lucas J.J., et al. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 20:2001;27-39.
14. Grimes C.A., Jope R.S. The multifaceted roles of glycogen synthase kinase-3β in cellular signaling. Prog. Neurobiol. 65:2001;391-426.
15. De Ferrari G.V., Inestrosa N.C. Wnt signaling function in Alzheimer's disease. Brain Res. Rev. 33:2000;1-12.
16. Inestrosa N., et al. Wnt signaling involvement in beta-amyloid-dependent neurodegeneration. Neurochem. Int. 41:2002;341-344.
17. Garrido J.L., et al. Protein kinase C inhibits amyloid beta peptide neurotoxicity by acting on members of the Wnt pathway. FASEB J. 16:2002;1982-1984.
18. Dale T. Signal transduction by the Wnt family of ligands. Biochem. J. 329:1998;209-223.
19. Servant L., et al. Involvement of DNA polymerase β in DNA replication and mutagenic consequences. J. Mol. Biol. 315:2002;1039-1047.
20. Su J.H., et al. Neuronal DNA damage precedes tangle formation and is associated with up-regulation of nitrotyrosine in Alzheimer's disease brain. Brain Res. 774:1997;193-199.
21. Koh J.Y., et al. Beta-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res. 533:1990;315-320.
22. Qin L., et al. Microglia enhance beta-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. J. Neurochem. 83:2002;973-983.
23. Minagar A., et al. The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J. Neurol. Sci. 202:2002;13-23.
24. Cotman C.W., Su J.H. Mechanisms of neuronal death in Alzheimer's disease. Brain Pathol. 6:1996;493-506.
25. Paradis E., et al. Amyloid beta peptide of Alzheimer's disease downregulates Bcl-2 and upregulates bax expression in human neurons. J. Neurosci. 16:1996;7533-7539.
26. Nagy Z.S., Esiri M.M. Apoptosis-related protein expression in the hippocampus in Alzheimer's disease. Neurobiol. Aging. 18:1997;565-571.
27. Willert K., Nusse R. β-catenin: a key mediator of Wnt signaling. Curr. Opin. Genet. Dev. 8:1998;95-102.
28. Murase S., et al. Depolarization drives beta-catenin into neuronal spines promoting changes in synpatic structure and function. Neuron. 35:2002;91-105.
29. Glinka A., et al. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature. 391:1998;357-362.
30. Wang J., et al. Dickkopf-1, an inhibitor of the Wnt signaling pathway, is induced by p53. Oncogene. 19:2000;1843-1848.
31. Caricasole A., et al. Expression of the Wnt antagonist Dkk1 is rapidly induced by β-amyloid peptide in cultured cortical neurons. Soc. Neurosci. Abstr. 91:2002;7.
32. Shaw M., et al. Further evidence that the inhibition of glycogen synthase kinase-3beta by IGF-1 is mediated by PDK1/PKB-induced phosphorylation of Ser-9 and not by dephosphorylation of Tyr-216. FEBS Lett. 416:1997;307-311.
33. Gasparini L., et al. Does insulin dysfunction play a role in Alzheimer's disease? Trends Pharmacol. Sci. 23:2002;288-293.
34. Liolitsa D., et al. Genetic variability in the insulin signalling pathway may contribute to the risk of late onset Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry. 73:2002;261-266.
35. Chenn A., Walsh C.A. Regulation of cerebral cortical size by control of cell cycle exit in neural precursors. Science. 297:2002;365-369.
36. Martin D., et al. Effect of the Alzheimer amyloid fragment Abeta(25-35) on Akt/PKB kinase and survival of PC12 cells. J. Neurochem. 78:2001;1000-1008.
37. Copani A., et al. Beta-amyloid-induced synthesis of the ganglioside GD3 is a requisite for cell cycle reactivation and apoptosis in neurons. J. Neurosci. 22:2002;3963-3968.
38. Copani A., et al. Activation of cell cycle-associated proteins in neuronal death: a mandatory or dispensable path? Trends Neurosci. 24:2001;25-31.
39. Mizushina Y., et al. The cyanogenic glucoside, prunasin (D-mandelonitrile-beta-D-glucoside), is a novel inhibitor of DNA polymerase beta. J. Biochem. 126:1999;430-436.
40. Xiang Z., et al. Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology. Neurobiol. Aging. 23:2002;327-334.
41. Derynck R. TGF-β receptor-mediated signaling. Trends Biochem. Sci. 19:1994;548-553.
42. Bruno V., et al. Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-beta. J. Neurosci. 18:1998;9594-9600.
43. D'Onofrio M., et al. Neuroprotection mediated by glial group-II metabotropic glutamate receptors requires the activation of the MAP kinase and the phosphatidylinositol-3-kinase pathways. J. Neurochem. 78:2001;435-445.
44. Helton D.R., et al. Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J. Pharmacol. Exp. Ther. 284:1998;651-660.
45. Honjo H., et al. Alzheimer's disease and estrogen. J. Steroid Biochem. Mol. Biol. 76:2001;227-230.
46. 2+ in hippocampal slices. Neuropharmacology. 38:1999;1253-1259.
47. Alvarez G., et al. Regulation of tau phosphorylation and protection against beta-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disord. 4:2002;153-165.
48. Eldar-Finkelman H. Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol. Med. 8:2002;126-132.
49. Damiens E., et al. Anti-mitotic properties of indirubin-3′-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest. Oncogene. 20:2001;3786-3797.
50. Leclerc S., et al. Indirubins inhibit glycogen synthase kinase-3β and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. J. Biol. Chem. 276:2001;251-260.
51. Fukumoto S., et al. Akt participation in the Wnt signaling pathway through dishevelled. J. Biol. Chem. 276:2001;17479-17483.